Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Liu Qiang, Chairman of YaoPharma, said: "By leveraging Pfizer's exceptional global development experience and commercialisation network, along with YaoPharma's profound expertise in small molecule R&D and manufacturing, our shared goal is to accelerate the global development and commercialisation of this innovative drug, thereby benefiting patients worldwide more rapidly and extensively." Pfizers moves with Metsera and now YaoPharma add to continued competition in the obesity drug market, which has also seen Teva Pharmaceuticals gain US Food and Drug Administration (FDA) approval in August of a generic GLP-1 of its version of Novo Nordisks injectable Saxenda (liraglutide).
Bonus: Bean-rich soup recipes tend to incorporate other nutrient-rich veggies, Bakovic says
Current research does not show that BPC-157 directly causes weight loss
Is oral tirzepatide as good as injected
